Search

Jerzy A Olejnik

from Sudbury, MA
Age ~62
Get Report
Related to:
Edyta Olejnik, 61Katarzyna L Olejnik, 33
Connected to:
Agnieszka Olejnik, 42Alan S Olejnik, 34Elena E Olejnik, 48Krystyna B Olejnik, 73Loralee R Olejnik, 44Melissa J Olejnik, 54Orest Olejnik, 69Peter N Olejnik, 74Jan Olek, 73

Jerzy Olejnik Phones & Addresses

  • Sudbury, MA
  • 48 Beaconsfield Rd, Brookline, MA 02445 (617) 232-7309
  • 48 Beaconsfield Rd APT 2, Brookline, MA 02445 (617) 232-7309
  • 99 Boylston St, Brookline, MA 02445 (617) 232-7309
  • Allston, MA

Resumes

Resumes

Jerzy Olejnik Photo 1

Vice President And Head, Ngs Technologies, Global Development

View page
Location:
Brookline, MA
Industry:
Biotechnology
Work:
Qiagen
Vice President and Head, Ngs Technologies, Global Development
Intelligent Bio-Systems, Inc.- A Qiagen Company 2012 - 2014
Chief Technology Officer
Intelligent Bio-Systems, Inc.- A Qiagen Company 2006 - 2012
Vp, R and D
Boston University Questrom School of Business 2003 - 2005
Emba 17 Student
Ambergen 1996 - 1998
Senior Scientist and Project Manager
Education:
Boston University 2004 - 2005
Master of Business Administration, Masters, Management A.mickiewicz University, Poznan 1986 - 1990
Doctorates, Doctor of Philosophy, Organic Chemistry A. Mickiewicz University, Poznan, Poland Oct 1981 - May 1986
Master of Science, Masters, Chemistry
Skills:
Biotechnology
R&D
Technology Transfer
Strategy
Business Development
Strategic Planning
Product Development
Patents
Commercialization
Management
Life Sciences
Chemistry
Cross Functional Team Leadership
Lifesciences
Molecular Biology
Organic Chemistry
Biochemistry
Research and Development
Leadership
Purification
Medical Devices
Validation
Research
Engineering
Licensing
Outsourcing
Product Management
Fda
Marketing Strategy
Start Ups
Genomics
Ngs
Competitive Intelligence
Jerzy Olejnik Photo 2

Jerzy Olejnik

View page
Location:
Greater Boston Area
Industry:
Biotechnology
Skills:
Biotechnology
R&D
Business Development
Strategic Planning
Patents

Business Records

Name / Title
Company / Classification
Phones & Addresses
Jerzy Olejnik
President, Chief Executive Officer
MCR BIOSCIENCES, INC
Commercial Physical Research
48 Beaconsfield Rd, Brookline, MA 02445
Jerzy Olejnik
Engineer
Apredica
Pharmaceuticals · Commercial Physical Research
313 Pleasant St, Watertown, MA 02472
(617) 923-6400
Jerzy Olejnik
Manager
BIO-COMM, LLC
48 Beaconsfield Rd, Brookline, MA 02445

Publications

Us Patents

Electrophoresis Of Nascent Proteins

View page
US Patent:
6344320, Feb 5, 2002
Filed:
May 7, 1999
Appl. No.:
09/307579
Inventors:
Kenneth J. Rothschild - Newton MA
Sanjay M. Sonar - Mumbai, IN
Jerzy Olejnik - Allston MA
Assignee:
The Trustees of Boston University - Boston MA
International Classification:
C12Q 168
US Classification:
435 6, 435 911, 435 912
Abstract:
The invention is directed to methods for the non-radioactive labeling, detection, quantitation and isolation of nascent proteins translated in a cellular or cell-free translation system. tRNA molecules are misaminoacylated with non-radioactive markers which may be non-native amino acids, amino acid analogs or derivatives, or substances recognized by the protein synthesizing machinery. Markers may comprise cleavable moieties, detectable labels, reporter properties wherein markers incorporated into protein can be distinguished from unincorporated markers, or coupling agents which facilitate the detection and isolation of nascent protein from other components of the translation system. The invention also comprises proteins prepared using misaminoacylated tRNAs which can be utilized in pharmaceutical compositions for the treatment of diseases and disorders in humans and other maninials, and kits which may be used for the detection of diseases and disorders.

Detection Of Markers In Nascent Proteins

View page
US Patent:
6358689, Mar 19, 2002
Filed:
May 31, 2000
Appl. No.:
09/583243
Inventors:
Kenneth J. Rothschild - Newton MA
Jerzy Olejnik - Allston MA
Assignee:
Boston University - Boston MA
International Classification:
C12Q 168
US Classification:
435 6, 435 691
Abstract:
The invention is directed to methods for the non-radioactive labeling, detection, quantitation and isolation of nascent proteins translated in a cellular or cell-free translation system. tRNA molecules are misaminoacylated with non-radioactive markers which may be non-native amino acids, amino acid analogs or derivatives, or substances recognized by the protein synthesizing machinery. Markers may comprise cleavable moieties, detectable labels, reporter properties wherein markers incorporated into protein can be distinguished from unincorporated markers, or coupling agents which facilitate the detection and isolation of nascent protein from other components of the translation system. The invention also comprises proteins prepared using misaminoacylated tRNAs which can be utilized in pharmaceutical compositions for the treatment of diseases and disorders in humans and other mammals, and kits which may be used for the detection of diseases and disorders.

Detection Of Disease Related Genes

View page
US Patent:
6566070, May 20, 2003
Filed:
Aug 30, 2001
Appl. No.:
09/943120
Inventors:
Kenneth J. Rothschild - Newton MA
Sanjay M. Sonar - Mumbai, IN
Jerzy Olejnik - Allston MA
Assignee:
The Trustees of Boston University - Boston MA
International Classification:
C12Q 168
US Classification:
435 6, 435 911, 435 912
Abstract:
The invention is directed to methods for the non-radioactive labeling, detection, quantitation and isolation of nascent proteins translated in a cellular or cell-free translation system. tRNA molecules are misaminoacylated with non-radioactive markers which may be non-native amino acids, amino acid analogs or derivatives, or substances recognized by the protein synthesizing machinery. Markers may comprise cleavable moieties, detectable labels, reporter properties wherein markers incorporated into protein can be distinguished from unincorporated markers, or coupling agents which facilitate the detection and isolation of nascent protein from other components of the translation system. The invention also comprises proteins prepared using misaminoacylated tRNAs which can be utilized in pharmaceutical compositions for the treatment of diseases and disorders in humans and other maninials, and kits which may be used for the detection of diseases and disorders.

Photocleavable Agents And Conjugates For The Detection And Isolation Of Biomolecules

View page
US Patent:
6589736, Jul 8, 2003
Filed:
Feb 14, 2000
Appl. No.:
09/504001
Inventors:
Kenneth J. Rothschild - Newton MA
Sanjay M. Sonar - Boston MA
Jerzy Olejnik - Allston MA
Assignee:
The Trustees of Boston University - Boston MA
International Classification:
C12Q 168
US Classification:
435 6, 435 5, 536 221, 536 241, 536 2433, 536 253, 536 2532
Abstract:
This invention relates to agents and conjugates that can be used to detect and isolate target components from complex mixtures such as nucleic acids from biological samples, cells from bodily fluids, and nascent proteins from translation reactions. Agents comprise a detectable moiety bound to a photoreactive moiety. Conjugates comprise agents coupled to substrates by covalent bounds which can be selectively cleaved with the administration of electromagnetic radiation. Targets substances labeled with detectable molecules can be easily identified and separated from a heterologous mixture of substances. Exposure of the conjugate to radiation releases the target in a functional form and completely unaltered. Using photocleavable molecular precursors as the conjugates, label can be incorporated into macromolecules, the nascent macromolecules isolated and the label completely removed. The invention also relates to targets isolated with these conjugates which may be useful as pharmaceutical agents or compositions that can be administered to humans and other mammals.

Dual Markers

View page
US Patent:
6596481, Jul 22, 2003
Filed:
Jun 17, 1999
Appl. No.:
09/335018
Inventors:
Kenneth J. Rothschild - Newton MA
Jerzy Olejnik - Allston MA
Sanjay M. Sonar - Hiranadani Estate Thane, IN
Assignee:
AmberGen, Inc. - Boston MA
International Classification:
C12Q 168
US Classification:
435 6, 435 681, 435 691
Abstract:
The invention is directed to methods for the non-radioactive labeling, detection, quantitation and isolation of nascent proteins translated in a cellular or cell-free translation system. tRNA molecules are misaminoacylated with non-radioactive markers which may be non-native amino acids, amino acid analogs or derivatives, or substances recognized by the protein synthesizing machinery. Markers may comprise cleavable moieties, detectable labels, reporter properties wherein markers incorporated into protein can be distinguished from unincorporated markers, or coupling agents which facilitate the detection and isolation of nascent protein from other components of the translation system. The invention also comprises proteins prepared using misarminoacylated tRNAs which can be utilized in pharmaceutical compositions for the treatment of diseases and disorders in humans and other mammals, and kits which may be used for the detection of diseases and disorders.

Methods For The Detection, Analysis And Isolation Of Nascent Proteins

View page
US Patent:
6875592, Apr 5, 2005
Filed:
Mar 20, 2001
Appl. No.:
09/813197
Inventors:
Kenneth J. Rothschild - Newton MA, US
Sadanand Gite - Cambridge MA, US
Jerzy Olejnik - Allston MA, US
Assignee:
AmberGen, Inc. - Boston MA
International Classification:
C12P019/34
US Classification:
435 911, 435 4, 435 6, 536 231, 536 2532
Abstract:
This invention relates to non-radioactive markers that facilitate the detection and analysis of nascent proteins translated within cellular or cell-free translation systems. Nascent proteins containing these markers can be rapidly and efficiently detected, isolated and analyzed without the handling and disposal problems associated with radioactive reagents. Preferred markers are dipyrrometheneboron difluoride (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) dyes.

Detection Of Markers In Nascent Proteins

View page
US Patent:
6919179, Jul 19, 2005
Filed:
Dec 27, 2001
Appl. No.:
10/034736
Inventors:
Kenneth J. Rothschild - Newton MA, US
Jerzy Olejnik - Brookline MA, US
Sanjay M. Sonar - Thane, IN
Assignee:
The Trustees of Boston University - Boston MA
International Classification:
C12Q001/68
US Classification:
435 6, 435 701, 435 711, 536 241, 536 2532
Abstract:
The invention is directed to methods for the non-radioactive labeling, detection, quantitation and isolation of nascent proteins translated in a cellular or cell-free translation system. tRNA molecules are misaminoacylated with non-radioactive markers which may be non-native amino acids, amino acid analogs or derivatives, or substances recognized by the protein synthesizing machinery. Markers may comprise cleavable moieties, detectable labels, reporter properties wherein markers incorporated into protein can be distinguished from unincorporated markers, or coupling agents which facilitate the detection and isolation of nascent protein from other components of the translation system. The invention also comprises proteins prepared using misaminoacylated tRNAs which can be utilized in pharmaceutical compositions for the treatment of diseases and disorders in humans and other mammals, and kits which may be used for the detection of diseases and disorders.

Diagnosing Genetic Disorders

View page
US Patent:
6949341, Sep 27, 2005
Filed:
Oct 3, 2002
Appl. No.:
10/264126
Inventors:
Kenneth J. Rothschild - Newton MA, US
Sanjay M. Sonar - Boston MA, US
Jerzy Olejnik - Allston MA, US
Assignee:
The Trustees of Boston University - Boston MA
International Classification:
C12Q001/68
US Classification:
435 6, 435 911, 435 912
Abstract:
This invention relates to agents and conjugates that can be used to detect and isolate target components from complex mixtures such as nucleic acids from biological samples, cells from bodily fluids, and nascent proteins from translation reactions. Agents comprise a detectable moiety bound to a photoreactive moiety. Conjugates comprise agents coupled to substrates by covalent bounds which can be selectively cleaved with the administration of electromagnetic radiation. Targets substances labeled with detectable molecules can be easily identified and separated from a heterologous mixture of substances. Exposure of the conjugate to radiation releases the target in a functional form and completely unaltered. Using photocleavable molecular precursors as the conjugates, label can be incorporated into macromolecules, the nascent macromolecules isolated and the label completely removed. The invention also relates to targets isolated with these conjugates which may be useful as pharmaceutical agents or compositions that can be administered to humans and other mammals.
Control profile
Jerzy A Olejnik from Sudbury, MA, age ~62 Get Report